ACW actinogen medical limited

Apologies @dc1234 I was replying to your post but some of my...

  1. 513 Posts.
    lightbulb Created with Sketch. 20620
    Apologies @dc1234 I was replying to your post but some of my post was deleted. Anyway I guess this shouldn't be on a charting thread either way. But what I wanted to say in response to your post on where ACW was heading, was that as May June approaches the stock should slowly move up. May June is the date when 100 patients are forecast to have been dosed in the current and ongoing Xanamia late stage 2b/3 clinical trial for the drug. And I believe there are many who are aware of the Xanamemn story, believe in it, and are looking to get in. Unfortunately for them they are only going to have 24 weeks from when the 100th patients is announced to have been dosed to when interim results are announced, give or take a few weeks for screening. This going to put serious upward pressure on the stock, from where I sit.

    But hey, let's wait and see how it all pans out. No doubt there are still some Bell Potter holders who are sure to sell out for a few pips. They just sell the Heads for the Oppies and always lose out on the real chunk of change they could have made if they'd actually paid attentions to the real fundamentals in play, or should I say the real story. Unfortunately that's a little beyond their skill set, and beyond most of the day traders own the ASX.

    Opinions only
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
2.0¢
Change
0.000(0.00%)
Mkt cap ! $63.54M
Open High Low Value Volume
2.1¢ 2.1¢ 1.9¢ $89.16K 4.345M

Buyers (Bids)

No. Vol. Price($)
2 930170 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.1¢ 694274 3
View Market Depth
Last trade - 16.10pm 16/06/2025 (20 minute delay) ?
ACW (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.